Protein tyrosine kinase 7 (PTK7) is a cell-surface receptor linked to diverse cancer signaling pathways, including but not limited to, Wnt and VEGFR.
PTK7 lacks observable kinase activity but is overexpressed in a broad range of adult and pediatric solid tumors, and has been associated with poor prognosis and high metastatic potential. In contrast, normal tissues have limited expression of PTK7, making it a promising therapeutic target.
Antibody-drug conjugates (ADCs) are therapeutics formed by the fusion of an antibody to a potent cytotoxic drug or ‘payload’. The antibody portion guides the ADC to a cell-surface antigen overexpressed on cancer cells, such as PTK7, enabling delivery of the cytotoxic payload specifically to the tumor, resulting in tumor cell death, whilst potentially minimizing impact on normal tissues.
Learn more about our clinical trial for patients with advanced/metastatic solid tumors